JHX
Hardies doing their level best to confuse everyone. Upgrades continue, if you can believe.

Mgmt suggest the AZEK acquisition is outperforming expectations, which is pleasing to hear, for what has to be the most universally hated bit of M&A since Vifor by CSL.
US housing markets remain challenged, as they do pretty much everywhere (Europe, Australia) given high-ish interest rates and poor affordability. In the interim, it seems JHX are focused on trying to take cost out of the business (manufacturing efficiencies) whilst finding ways to get revenue synergies out of AZEK (the acquisition rationale was more or less “when people reno the house they often think about doing the deck as well, and so we combined the two companies that were #1 in each of those things”).
It would seem, based on today, that idea is holding up okay. Although the detailed bits we highlighted above, clearly the below headlines are good “raises FY26 sales and EBITDA guide”.

It also seems fair to assume that when housing eventually stabilises, JHX will be in a very good position.
SDF
Interesting to see the Steadfast CEO inquiry has “wrapped up”. Recall this announcement (that he was stepping aside pending investigation) in part caused a 20% drop in the share price in the days (minutes) following. Whilst that amount hasn’t been “wiped back on”, we do take it as an overall positive for company stability.

Important Information: This document has been prepared by Aequitas Investment Partners Pty Ltd ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of AIP FS Pty Ltd ABN 49 680 982 478 (Australian Financial Services Licensee no. 700016) and is for distribution within Australia to wholesale clients only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Aequitas is not authorised to provide tax (financial) advice and is not a registered tax agent. Investors should seek their own tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law. We recommend that you consult a registered tax agent or a tax specialist to confirm your taxation position.